The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).
Anas Younes
Consultant or Advisory Role - Millennium; Seattle Genetics
Honoraria - Millennium; Seattle Genetics
John Radford
Consultant or Advisory Role - Millennium
Honoraria - Millennium; Seattle Genetics
Research Funding - Millennium
Stephen Maxted Ansell
No relevant relationships to disclose
Andrea Gallamini
Consultant or Advisory Role - Seattle Genetics
Won Seog Kim
Consultant or Advisory Role - Celltrion
Tatyana A. Feldman
Honoraria - Celgene; Seattle Genetics; Spectrum Pharmaceuticals
Mehdi Hamadani
No relevant relationships to disclose
Jeanenne Chung
Employment or Leadership Position - Millennium
Jingyuan Wang
Employment or Leadership Position - Millennium
Stock Ownership - Takeda
Dirk Huebner
Employment or Leadership Position - Millennium
Stock Ownership - Takeda
Joseph M. Connors
Research Funding - Millennium; Seattle Genetics